Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MAXXON, INC (MXON.Nasdaq BB) Disposable syringe technology -- Ignore unavailable to you. Want to Upgrade?

To: bcjt who wrote (64)	3/18/1999 9:40:00 AM
From: bcjt	Respond to of 105

PRESS RELEASE Maxxon Appoints Medical Director Maxxon Appoints Medical Director TULSA, OKLA. (March 17) BW HEALTHWIRE -March 17, 1999--Maxxon, Inc. (OTCBB: MXON) today announced the appointment of Thomas R. Coughlin, Jr., M.D., as Medical Director for the corporation. In this capacity, Dr. Coughlin will directly oversee the engineering and development of Maxxon's patented disposable Safety Syringe(TM). The syringe, which is in pre-production testing stage, automatically retracts the needle into the barrel of the plunger after use, thereby helping to prevent accidental needlestick injuries. Dr. Coughlin will also review current regulatory and legislative developments pertaining to the prevention of accidental needlesticks and will help Maxxon initiate advocacy outreach programs on the state and national levels. Dr. Coughlin is a graduate of Seton Hall University and the University of Rochester School of Medicine. He has completed postgraduate training in general surgery, cardiothoracic surgery, vascular surgery and transplant surgery, and is board certified in both general and thoracic surgery. He began the cardiac transplant program at the University of Texas, Galveston in 1984 and was Chief of Transplant Surgery at the University of Maryland from 1986 to 1990. He served as Director of Cardiac Surgery at Alexandria Hospital in Alexandria, Virginia from 1990 to 1995 and came to Tulsa as an associate of Dr. Bill Loughridge in 1995. Dr. Coughlin is a member of numerous national medical societies and organizations and has several publications to his credit. His wide and varied experience in clinical medicine, teaching and research will help to ensure that Maxxon is well positioned in the medical manufacturing sector. The Maxxon Safety Syringe is expected to have a worldwide market, as injuries with contaminated needles are a danger to healthcare workers everywhere. According to engineers engaged by Maxxon, the Safety Syringe is believed to be capable of being produced and marketed at a cost competitive with standard disposable non-safety syringes. "When you have a cost competitive, disposable safety syringe available, why would you consider purchasing the alternative?" stated Dr. Coughlin. "This simple device could save hundreds of lives in the United States alone, and greatly reduce the estimated 1,000,000 annual needlestick injuries suffered by America's 8.8 million healthcare workers," added Dr. Coughlin. Maxxon expects to have the initial pilot production run of its Safety Syringe in the next few weeks. As high speed production processes are initiated, the company eventually expects to be able to produce up to 1, 000,000 syringes per day. With an estimated 15 billion syringes used worldwide on an annual basis, the market for the Maxxon Safety Syringe is substantial. This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainties, including, without limitation, the ability of Maxxon, Inc. to accomplish its stated plan of business. Although Maxxon believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate and, therefore, there can be no assurance that the forward-looking statements included in this press release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by Maxxon or any other person that the objectives and plans of Maxxon will be achieved. -0- SH/dx* bcjt

To: bcjt who wrote (64)	3/18/1999 9:43:00 AM
From: bcjt	Respond to of 105

HUGE DISCLAIMER !!!!!!!!WHY!!! This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainties, including, without limitation, the ability of Maxxon, Inc. to accomplish its stated plan of business. Although Maxxon believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate and, therefore, there can be no assurance that the forward-looking statements included in this press release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by Maxxon or any other person that the objectives and plans of Maxxon will be achieved You think they could of made it longer!!! bcjt